NCT01230619

Vienna Challenge Chamber Study Using RV658 in Subjects With Allergic Rhinitis

A Two Day, Randomised, Single Blind, Parallel Group Trial of Repeat Doses of Intranasal RV568 in the Vienna Challenge Chamber in Subjects With Seasonal Allergic Rhinitis (SAR)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 75 (actual)
• Sponsor: Respivert Ltd · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

RV568 is being developed for the treatment of diseases such as asthma, COPD and allergic rhinitis (e.g. hayfever). The main aim of this study is to investigate whether RV568 ameliorates the nasal symptoms to low doses of grass pollen in healthy subjects with seasonal allergic rhinitis.

Conditions

• Seasonal Allergic Rhinitis

Interventions

Type	Name	Description
DRUG	RV568	RV568 400 ug administered as nasal drops twice daily on Day 1, RV568 800 ug administered as nasal drops once daily on Day 2
DRUG	Placebo	Placebo administered as nasal drops twice daily on Day 1, Placebo administered as nasal drops once daily on Day 2

Timeline

• Start date: 2010-10-01
• Primary completion: 2010-11-01
• Completion: 2010-12-01
• First posted: 2010-10-29
• Last updated: 2010-12-06

Locations

1 site across 1 country: Austria